FT 005
Alternative Names: FT-005Latest Information Update: 03 Aug 2022
At a glance
- Originator Frontera Therapeutics
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Haematological disorders
Most Recent Events
- 22 Jul 2022 FT 005 is available for licensing as of 22 Jul 2022. https://www.fronteratherapeutics.com/about/
- 22 Jul 2022 Preclinical trials in Haematological disorders in USA (Parenteral) (Frontera Therapeutics pipeline, July 2022)